| Previous Close | 0.6005 |
| Open | 0.6001 |
| Bid | 0.5675 x 26100 |
| Ask | 0.6500 x 5000 |
| Day's Range | 0.6000 - 0.6149 |
| 52 Week Range | 0.4600 - 3.3500 |
| Volume | 333,448 |
| Avg. Volume | 402,245 |
| Market Cap | 21.62M |
| Beta | 0.55 |
| PE Ratio (TTM) | -1.39 |
| EPS (TTM) | -0.43 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.63 |
- ACCESSWIRE•4 days ago
Heat Biologics Announces Common Stock Rights Offering in Form S-1 Filing
DURHAM, NC / ACCESSWIRE / September 15, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•5 days ago
Heat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance with Listing Requirements
DURHAM, NC / ACCESSWIRE / September 14, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•6 days ago
Today's Research Reports on Stocks to Watch: Advaxis and Heat Biologics
NEW YORK, NY / ACCESSWIRE / September 13, 2017 / Heat Biologics saw a gain on Tuesday after announcing that it has been granted a Type C FDA meeting to discuss its non-small cell lung cancer (NSCLC) trial ...
